Skip to main content
    I

    Innate Pharma (IPHA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.39
    +0.01 (+0.72%)

    Market Cap: $154.15M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Innate Pharma (IPHA) Financials: Revenue, Profit and Cash Flow

    Updated Sep 17, 2026. Financial statements from company filings, amounts in EUR.

    Innate Pharma reported revenue of EUR 2.79M for the fiscal year ended Dec 31, 2025, down 77.9% from the year before. That year, net income was EUR -49.18M with a net margin of -1764.5%, operating cash flow was EUR -32.56M and free cash flow was EUR -34.91M. The quarter ended Jun 30, 2026 had revenue of EUR 5.66M and net income of EUR -19.62M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from EUR 56.16M, a compound annual decline of 28.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 20252.79M-77.9%100.0%-1916.9%-1764.5%
    Dec 202412.62M-75.7%100.0%-408.6%-392.0%
    Dec 202351.90M-10.0%10.8%-24.4%-14.6%
    Dec 202257.67M+376.2%10.4%-99.6%-100.7%
    Dec 202112.11M-82.6%-184.1%-394.9%-436.0%
    Dec 202069.77M+1.2%28.8%1.5%-91.7%
    Dec 201968.97M-13.7%34.5%-39.2%-30.1%
    Dec 201879.89M+144.8%12.9%6.4%3.8%
    Dec 201732.63M-41.9%-105.3%-122.5%-148.3%
    Dec 201656.16MN/A13.4%13.5%22.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue2.79M12.62M51.90M57.67M12.11M69.77M68.97M79.89M32.63M56.16M
    Cost of revenueN/A51.98M56.02M51.66M47.00M49.71M45.16M69.56M67.00M48.63M
    Gross profit2.79M12.62M5.62M6.01M-22.30M20.07M23.82M10.34M-34.37M7.53M
    Research and development43.62M51.98M56.02M51.66M47.00M49.71M1.60M69.56M67.00M48.63M
    Operating income-53.42M-51.58M-12.67M-57.42M-47.83M1.08M-27.05M5.15M-39.98M7.57M
    Net income-49.18M-49.47M-7.57M-58.10M-52.81M-63.98M-20.76M3.05M-48.38M12.64M
    EBITDA-43.65M-46.91M-1.84M-12.28M-43.23M57.88M18.10M12.55M-35.59M10.83M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Jun 2025Mar 2025Dec 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Revenue5.66M-2.07M-2.07M4.86M276.00K276.00K12.35M16.56M21.44M10.72M35.34M20.10M
    Gross profit5.66M18.45M18.45M-15.66M29.35M29.35M-16.73M-3.13M-3.13M-1.56M19.62M4.37M
    Operating income-19.01M-28.00M-28.00M-25.43M-25.26M-25.26M-26.31M-7.42M-12.27M-6.13M-5.25M-199.50K
    Net income-19.62M-27.63M-27.63M-21.34M-24.71M-24.71M-24.76M-9.29M-9.29M-4.64M1.72M859.00K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of EUR 22.48M by 5.60M. Shareholder equity was negative, at -21.69M, as total liabilities of 84.39M exceeded total assets of 62.69M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets62.69M111.06M175.19M207.86M267.50M307.42M401.36M451.22M255.02M281.58M
    Current assets46.69M85.74M148.01M139.83M138.26M173.33M237.60M319.64M137.52M230.08M
    Cash and equivalents28.08M66.40M70.61M84.22M103.76M136.79M202.89M152.31M99.37M175.91M
    Total liabilities84.39M102.22M132.29M153.71M160.06M151.45M183.94M283.98M169.07M195.41M
    Short-term debt8.80M8.71M8.94M2.10M30.75M2.14M2.13M1.35M1.34M1.26M
    Long-term debt13.67M22.18M30.61M38.93M13.50M16.95M14.10M2.03M2.42M1.05M
    Shareholder equity-21.69M8.83M51.90M54.15M107.44M155.97M217.42M167.24M85.96M86.17M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Jun 2025Mar 2025Dec 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total assets34.71M62.69M62.69M92.94M111.06M111.06M151.50M175.19M184.19M184.19M199.05M207.86M
    Total liabilities75.20M84.39M84.39M87.79M102.22M102.22M122.70M123.29M132.29M132.29M141.19M153.71M
    Cash and equivalents6.46M28.08M28.08M53.70M66.40M66.40M69.99M70.61M70.61M70.61M71.41M84.22M
    Shareholder equity-40.49M-21.69M-21.69M5.14M8.83M8.83M28.80M51.90M51.90M51.90M57.86M54.15M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-32.56M-6.90M-32.56M-19.15M-58.46M-51.81M34.92M-32.53M-48.06M-36.85M
    Capital expenditures2.35M391.00K351.00K1.12M1.33M11.28M65.40M1.43M6.03M9.39M
    Free cash flow-34.91M-7.29M-32.91M-20.28M-59.79M-63.09M-30.48M-33.96M-54.09M-46.24M
    Investing cash flow20.63M9.20M20.63M1.88M-917.00K-13.37M-62.12M24.28M-29.46M60.51M
    Financing cash flow-1.97M-6.01M-1.97M-1.83M26.82M-1.14M77.77M61.22M915.00K-602.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Jun 2025Mar 2025Dec 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating cash flow-21.33M-23.40M-23.40M-31.16M-9.93M-9.93M3.04M-21.09M-21.09M-10.55M-11.46M-20.20M
    Capital expenditures91.21K85.05K85.05K58.00K108.00K108.00K283.00K42.00K42.00K21.00K312.00K702.00K
    Free cash flow-21.42M-23.48M-23.48M-31.22M-10.04M-10.04M2.75M-21.14M-21.14M-10.57M-11.78M-20.91M
    Last 12 quarters

    Frequently Asked Questions About IPHA

    What is Innate Pharma's annual revenue?

    Innate Pharma reported revenue of EUR 2.79M for the fiscal year ended Dec 31, 2025.

    How fast is Innate Pharma's revenue growing?

    Revenue was down 77.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -63.6%.

    Is Innate Pharma profitable?

    No. Innate Pharma reported net income of EUR -49.18M for the fiscal year ended Dec 31, 2025, with a net margin of -1764.5%.

    How much free cash flow does IPHA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of EUR -32.56M minus capital expenditures of EUR 2.35M produced free cash flow of EUR -34.91M.

    How much debt does Innate Pharma have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of EUR 13.67M, short-term debt of EUR 8.80M and cash and equivalents of EUR 28.08M.